Equity Overview
Price & Market Data
Price: $34.90
Daily Change: +$3.02 / 8.65%
Daily Range: $32.27 - $36.83
Market Cap: $3,584,746,496
Daily Volume: 589,637
Performance Metrics
1 Week: -5.43%
1 Month: 5.60%
3 Months: 18.03%
6 Months: -1.51%
1 Year: -39.91%
YTD: -20.78%
Company Details
Employees: 36
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.